Suchergebnisse - "Perrone, Francesco"

PubPharm (142)

1

Off-label prescription of antineoplastic drugs : an Italian prospective, observational, multicenter survey

enthalten in: Tumori | 2009

von Roila, F. | Ballatori, E. | Labianca, R. | +32

2

Trastuzumab beyond progression : is the risk of cardiac toxicity really not increased?

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2009

von Morabito, A. | Piccirillo, M. | De Maio, E. | +2

CommentOn: J Clin Oncol. 2009 Apr 20;27(12):1999-2006. - PMID 19289619

3

Target-based therapies in breast cancer : current status and future perspectives

enthalten in: Endocrine-related cancer | 2009

von Normanno, N. | Morabito, A. | De Luca, A. | +4

4

Targeted therapies : Role of sorafenib in HCC patients with compromised liver function

enthalten in: Nature reviews. Clinical oncology | 2009

von Di Maio, M. | Daniele, B. | Perrone, F.

5

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function

enthalten in: Nature Clinical Practice / Oncology | 2009

von Di Maio, M. | Daniele, B. | Perrone, F.

6

Target-based therapies in breast cancer: current status and future perspectives

enthalten in: Endocrine related cancer | 2009

von Normanno, N. | Morabito, A. | De Luca, A. | +4

7

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer : the HOBOE trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2009

von Rossi, E. | Morabito, A. | Di Rella, F. | +16

CommentIn: J Clin Oncol. 2010 Feb 20;28(6):e101-2; author reply e103-4. - PMID 20085930

8

Registrative trials of antiemetic drugs : arrival or starting point?

enthalten in: The Lancet. Oncology | 2009

von Di Maio, M. | Perrone, F.

CommentOn: Lancet Oncol. 2009 Jun;10(6):549-58. - PMID 19428297

9

Registrative trials of antiemetic drugs: arrival or starting point?

enthalten in: The lancet / Oncology | 2009

von Di Maio, M. | Perrone, F.

10

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases : current status and future directions

enthalten in: The oncologist | 2009

von Morabito, A. | Piccirillo, M. | Falasconi, F. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]